S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

ValiRx Stock Price, News & Analysis (LON:VAL)

GBX 0.14
0.00 (0.00 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
0.13
Now: GBX 0.14
0.14
50-Day Range
0.13
MA: GBX 0.16
0.25
52-Week Range
0.12
Now: GBX 0.14
2
Volume10.33 million shs
Average Volume3.82 million shs
Market Capitalization£1.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-30084416

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.09 per share
Book ValueGBX 0.30 per share

Profitability

Miscellaneous

Employees12
Outstanding Shares1,024,060,032
Market Cap£1.38 million
Next Earnings DateN/A
OptionableNot Optionable

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.


ValiRx (LON:VAL) Frequently Asked Questions

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How were ValiRx's earnings last quarter?

ValiRx Plc (LON:VAL) announced its quarterly earnings results on Tuesday, April, 10th. The company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.60) by $0.70. View ValiRx's Earnings History.

Has ValiRx been receiving favorable news coverage?

News articles about VAL stock have trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ValiRx earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for ValiRx.

Who are some of ValiRx's key competitors?

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), Boohoo Group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Solo Oil (SOLO), Cyanconnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

Who are ValiRx's key executives?

ValiRx's management team includes the folowing people:
  • Dr. Satu Vainikka, Founding Director & CEO (Age 52)
  • Mr. James Gerry Desler, Founding Director & CFO (Age 63)
  • Dr. George Morris, Founding Director & COO (Age 63)
  • Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 63)
  • Mr. Tarquin Edwards, Head of Investor Relations & Communications

How do I buy shares of ValiRx?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 0.14.

How big of a company is ValiRx?

ValiRx has a market capitalization of £1.38 million. ValiRx employs 12 workers across the globe.View Additional Information About ValiRx.

What is ValiRx's official website?

The official website for ValiRx is http://www.valirx.com/.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.


MarketBeat Community Rating for ValiRx (LON VAL)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe VAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel